Top 5 Drug Type | Count |
---|---|
Proteolysis-targeting chimeras (PROTAC) | 40 |
Small molecule drug | 10 |
Oncolytic virus | 1 |
Recombinant polypeptide | 1 |
Chemical drugs | 1 |
Target |
Mechanism miR-204-5p inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism STAT3 inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism STAT3 inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date01 Jun 2025 |
Sponsor / Collaborator |
Start Date01 May 2025 |
Sponsor / Collaborator |
Start Date01 May 2025 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
GDC-2 ( GPX4 ) | Neoplasms More | Preclinical |
Tauroursodeoxycholate sodium ( α5β1 ) | Colitis, Ulcerative More | Preclinical |
HDAC8 inhibitors(Zhejiang Chinese Medical University) ( HDAC8 ) | Breast Cancer More | Preclinical |
Salvianolic acid A ( miR-204-5p ) | Endothelial dysfunction More | Preclinical |
GDC-19 ( GPX4 ) | Neoplasms More | Preclinical |